Want to see PPCB full AI Analyst Report?
Propanc Biopharma (PPCB) Ratios
Propanc Biopharma Ratios
PPCB's free cash flow for Q4 2026 was $-1.60M. For the 2026 fiscal year, PPCB's free cash flow was decreased by $-21.00 and operating cash flow was $-1.60M. See a summary of the company’s cash flow.
| Ratios | Jun 26 | Jun 25 | Jun 24 | Jun 23 | Jun 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.55 | 1.50 | 0.01 | 0.01 | 0.00 |
| Quick Ratio | 2.55 | 1.50 | 0.01 | 0.01 | 0.00 |
| Cash Ratio | 0.25 | 0.00 | 0.01 | 0.00 | 0.00 |
| Solvency Ratio | -5.58 | -10.29 | -0.47 | -0.83 | -0.86 |
| Operating Cash Flow Ratio | -1.69 | -0.07 | -0.25 | -0.35 | -0.47 |
| Short-Term Operating Cash Flow Coverage | -232.05 | -0.26 | -1.07 | -2.19 | -1.47 |
| Net Current Asset Value | $ 5.16M | $ 2.63M | $ -3.83M | $ -3.16M | $ -3.09M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.09 | 13.10 | 9.05 | 12.74 |
| Debt-to-Equity Ratio | 0.01 | 0.12 | -0.25 | -0.18 | -0.34 |
| Debt-to-Capital Ratio | 0.01 | 0.11 | -0.33 | -0.21 | -0.52 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.01 | -0.02 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.36 | 1.41 | -0.02 | -0.02 | -0.03 |
| Debt Service Coverage Ratio | -40.46 | -27.45 | -0.74 | -2.03 | -1.35 |
| Interest Coverage Ratio | -42.24 | -101.60 | -2.31 | -3.34 | -3.50 |
| Debt to Market Cap | 0.03 | 0.10 | 8.40 | 0.62 | 44036.44 |
| Interest Debt Per Share | 4.26 | 144.31 | 1139.11 | 10787.37 | 536443.67 |
| Net Debt to EBITDA | 0.04 | -0.03 | -0.73 | -0.24 | -0.48 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 93.38% | 95.38% | 97.97% |
| EBT Per EBIT | 103.72% | 102.87% | 126.95% | 157.01% | 136.26% |
| Return on Assets (ROA) | -147.60% | -300.14% | -2516.41% | -4410.89% | -3255.32% |
| Return on Equity (ROE) | -200.63% | -423.72% | 48.19% | 85.37% | 87.91% |
| Return on Capital Employed (ROCE) | -192.94% | -407.57% | 41.29% | 57.36% | 66.78% |
| Return on Invested Capital (ROIC) | -192.44% | -366.39% | 50.67% | 65.89% | 98.36% |
| Return on Tangible Assets | -147.60% | -300.14% | -2516.41% | -4410.89% | -3255.32% |
| Earnings Yield | -1119.07% | -357.80% | -1647.58% | -328.52% | -11972972.97% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.02 | 0.02 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -20450.10 | -19867.80 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 20450.10 | 19867.80 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -50.57 | -25.53 | -659.93 | -11052.51 | -478768.00 |
| Free Cash Flow Per Share | -50.57 | -25.53 | -659.93 | -11052.51 | -478768.00 |
| Dividend Paid and CapEx Coverage Ratio | -6.06 | -202584.00 | -467559.17 | -1105244.58 | -359075.50 |
| Capital Expenditure Coverage Ratio | -1151.50 | -202584.00 | -467559.17 | -1105244.58 | -359075.50 |
| Operating Cash Flow Coverage Ratio | -117.64 | -0.23 | -0.99 | -2.02 | -1.38 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -337.14% | -2.46% | -846.06% | -136.45% | -6469837.84% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.09 | -0.28 | -0.06 | -0.30 | -0.00 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.18 | 1.18 | -0.03 | -0.26 | -0.00 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.30 | -40.65 | -0.12 | -0.73 | -0.00 |
| Price-to-Operating Cash Flow Ratio | -0.30 | -40.65 | -0.12 | -0.73 | -0.00 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | -0.00 | 0.00 | 0.00 | -0.00 |
| Enterprise Value Multiple | -0.05 | -0.31 | -0.82 | -0.60 | -0.48 |
| Enterprise Value | 901.87K | 18.18M | 1.04M | 1.35M | 1.04M |
| EV to EBITDA | -0.05 | -0.31 | -0.82 | -0.60 | -0.48 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.16 | -44.88 | -1.11 | -1.22 | -0.72 |
| EV to Operating Cash Flow | -0.16 | -44.88 | -1.11 | -1.22 | -0.72 |
| Tangible Book Value Per Share | 83.67 | 876.09 | -2666.94 | -31171.79 | -1007883.00 |
| Shareholders’ Equity Per Share | 83.67 | 876.09 | -2666.94 | -31171.79 | -1007883.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.07 | 0.05 | 0.02 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -167.86 | -3712.17 | -1285.11 | -26610.00 | -886000.00 |
| Tax Burden | 1.00 | 1.00 | 0.93 | 0.95 | 0.98 |
| Interest Burden | 1.02 | 1.01 | 1.52 | 1.24 | 1.27 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.30 | 0.01 | 0.51 | 0.42 | 0.54 |
Currency in USD